ITUS Corporation Form 10-Q Summary
Reporting period: Three months ended January 31, 2015 (fiscal Q1); compared with the three months ended January 31, 2014. The supplied filing identifies the registrant as ITUS Corporation, not Anixa Biosciences Inc.; verify that this is the intended filing.
Business context and material event
ITUS develops, acquires, licenses, and enforces patented technologies. Its revenue is primarily generated through patent licensing and enforcement, often through one-time payments. The quarter’s results were dominated by the December 2014 AU Optronics (AUO) resolution: AUO paid $2 million to settle the dispute and $7 million for assignment of the ePaper patent portfolio. ITUS terminated AUO’s nFED license, regained unencumbered rights to that technology, and agreed not to bring certain patent infringement suits against AUO or affiliates for two years. The litigation and arbitration were dismissed with prejudice.
Financial results
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $9.135 million | $0 |
| Operating income (loss) | $3.857 million | $(1.965) million |
| Net income (loss) | $3.752 million | $(3.614) million |
| Operating costs and expenses | $5.278 million | $1.965 million |
| Operating cash flow | $4.653 million | $(1.172) million |
Q1 2015 revenue included $9.0 million from AUO and $135,000 from patent assertion activities. Approximate operating and net margins were 42% and 41%, respectively, but are not representative of recurring performance given the settlement-related revenue. AUO-related litigation and licensing expenses were approximately $3.335 million; total contingent legal fees and litigation costs related to the dispute were approximately $3.604 million, of which $3.5 million was paid during the quarter. Patent amortization was $81,000. Interest expense was $109,000, primarily amortized interest on the patent acquisition obligation; there was no income-tax provision, with management expecting net operating loss carryforwards to offset taxable income.
Balance sheet, liquidity, and capital
- At January 31, 2015, cash and cash equivalents were $7.810 million and short-term certificates of deposit were $2.650 million, totaling approximately $10.460 million in cash and short-term investments. Cash and investments increased approximately $4.599 million from October 31, 2014.
- Current assets were $10.571 million versus current liabilities of $1.667 million. Total liabilities were $5.013 million; these included a $3.345 million patent acquisition obligation due no later than November 2017, payable at the company’s option in cash or common stock for the final payment.
- There were no financing cash flows in the quarter. Investing cash use was $205,000, including property and equipment purchases, net of certificate-of-deposit maturities.
- Management stated that available resources and expected cash flows should fund operations for at least 12 months, based on information available March 9, 2015. It cautioned that future licensing cash flows and financing availability are uncertain; additional equity or convertible debt could dilute shareholders, and insufficient funding could require reduced or discontinued operations.
- Common shares outstanding were 219.712 million at January 31, 2015. Basic and diluted EPS were each $0.02; diluted weighted-average shares were 231.288 million. Substantial options and warrants remain outstanding.
Changes, outlook, risks, and unusual items
- Compared with Q1 2014, the company moved from a loss to a profit, principally because of the AUO proceeds. Litigation and licensing expense rose from $33,000 to $3.335 million. Marketing, general and administrative expense declined about $88,000 to $1.773 million.
- Interest expense fell from $379,000 to $109,000; the prior-year period included convertible-debenture discount amortization and derivative-liability losses. ITUS reported no convertible debentures at October 31, 2014.
- Patent acquisition obligations increased to $3.345 million, reflecting $109,000 of amortized interest. The filing reports no material change in previously disclosed risk factors and no material pending legal proceedings apart from ordinary-course patent enforcement matters.
- After quarter-end, on February 5, 2015, the company reset the exercise price to $0.103 for options covering 54.603 million shares held by employees, former employees, and directors. On March 5, it repurchased 800,000 shares from a former employee at $0.25 per share and cancelled the related warrant.
- Management gave no specific revenue or earnings forecast. The business depends on patent licensing and enforcement, and individual license and settlement payments are generally nonrecurring. Results for the quarter are not necessarily indicative of full-year results.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for ITUS Corporation, whereas the request names Anixa Biosciences Inc.
- Review the AUO settlement terms, including the ePaper patent assignment, the two-year litigation restriction, and the accounting and cash timing of the $9 million proceeds and settlement costs.
- Assess whether recurring patent licensing or enforcement revenue can support operations after the one-time AUO proceeds.
- Review the patent acquisition obligation’s payment terms and fair-value estimate, and the potential dilution from outstanding options, warrants, and any future financing.
- Evaluate management’s 12-month liquidity assertion against actual cash use, future operating costs, and the availability of additional funding.